Influence of dexmedetomidine on cardiac complications in non-cardiac surgery: a meta-analysis of randomized trials

Influence of dexmedetomidine on cardiac complications in non-cardiac surgery: a meta-analysis of... Background The cardiac protection of dexmedetomidine (Dex) in peri-operative period of patients with non-cardiac surgery is still controversial. Aim of the Review We aimed to evaluate the influence of Dex on cardiac complications in peri-operative period of non-cardiac surgery by using a meta-analysis. Methods PubMed, Embase, the Cochrane library and Springer databases were searched for relevant studies. Patients in the eligible studies were divided into Dex group and placebo group. Relative risk (RR) and the 95 % confidence interval (CI) were calculated to evaluate the outcomes including all-cause mortality, myocardial infarction, myocardial ischaemia, hypotension and bradycardia. Subgroup analysis was performed based on the dosage of Dex. Publication bias was assessed by Egger’s test. Results Twenty double-blind randomized controlled trials containing 1157 patients were included in this meta-analysis. The pooled results showed no significant difference between Dex group and placebo group in peri-operative myocardial infarction, myocardial ischaemia and all-cause mortality. However, Dex group showed higher risk of hypotension (RR = 1.46, 95 % CI 1.07, 2.01) and bradycardia (RR = 1.98, 95 % CI 1.33, 2.95) than that of placebo group. In addition, significant publication bias was found among studies involving hypotension and bradycardia. In subgroup analysis, the risk of bradycardia was significantly higher in 1.0 μg/kg Dex group than that in placebo group. Besides, a higher risk of hypotension in 0.5 μg/kg Dex group than that in placebo group was found. Conclusions Dex supplement might not reduce the risk of cardiac complications but increases the risk of hypotension and bradycardia in peri-operative period of patients who underwent non-cardiac surgeries. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Clinical Pharmacy Springer Journals

Influence of dexmedetomidine on cardiac complications in non-cardiac surgery: a meta-analysis of randomized trials

Loading next page...
 
/lp/springer_journal/influence-of-dexmedetomidine-on-cardiac-complications-in-non-cardiac-HZxmi2tFT2
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing
Subject
Medicine & Public Health; Internal Medicine; Pharmacy
ISSN
2210-7703
eISSN
2210-7711
D.O.I.
10.1007/s11096-017-0493-8
Publisher site
See Article on Publisher Site

Abstract

Background The cardiac protection of dexmedetomidine (Dex) in peri-operative period of patients with non-cardiac surgery is still controversial. Aim of the Review We aimed to evaluate the influence of Dex on cardiac complications in peri-operative period of non-cardiac surgery by using a meta-analysis. Methods PubMed, Embase, the Cochrane library and Springer databases were searched for relevant studies. Patients in the eligible studies were divided into Dex group and placebo group. Relative risk (RR) and the 95 % confidence interval (CI) were calculated to evaluate the outcomes including all-cause mortality, myocardial infarction, myocardial ischaemia, hypotension and bradycardia. Subgroup analysis was performed based on the dosage of Dex. Publication bias was assessed by Egger’s test. Results Twenty double-blind randomized controlled trials containing 1157 patients were included in this meta-analysis. The pooled results showed no significant difference between Dex group and placebo group in peri-operative myocardial infarction, myocardial ischaemia and all-cause mortality. However, Dex group showed higher risk of hypotension (RR = 1.46, 95 % CI 1.07, 2.01) and bradycardia (RR = 1.98, 95 % CI 1.33, 2.95) than that of placebo group. In addition, significant publication bias was found among studies involving hypotension and bradycardia. In subgroup analysis, the risk of bradycardia was significantly higher in 1.0 μg/kg Dex group than that in placebo group. Besides, a higher risk of hypotension in 0.5 μg/kg Dex group than that in placebo group was found. Conclusions Dex supplement might not reduce the risk of cardiac complications but increases the risk of hypotension and bradycardia in peri-operative period of patients who underwent non-cardiac surgeries.

Journal

International Journal of Clinical PharmacySpringer Journals

Published: Jun 28, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off